胍法辛对高血压患者血压及肾素活性的影响。
Effect of guanfacine on blood pressure and renin activity in hypertensive patients.
作者信息
Rosenthal J
出版信息
Br J Clin Pharmacol. 1980;10 Suppl 1(Suppl 1):91S-96S. doi: 10.1111/j.1365-2125.1980.tb04913.x.
Abstract
- The effect of treatment with guanfacine for 12 weeks on blood pressure and plasma renin activity was investigated in 24 hypertensive patients (WHO I-III). 2. Systolic, diastolic and mean blood pressure values underwent significant reductions with a constant dose of guanfacine 3 mg daily for 1 week: from 197/115/149 (systolic/diastolic/mean) mmHg before therapy to 166/97/126 mmHg. After 4 weeks of treatment at varying doses, the blood pressure decreased to 157/91/118 mmHg, and after 12 weeks of treatment it levelled off at 147/83/109 mmHg. Heart rate remained essentially unchanged throughout the observation period. 3. During exercise, blood pressure and heart rate increased to the same extent during therapy as before treatment. Orthostatic hypotension was not seen in any of the patients. 4. Renin values decreased under therapy from 3.3 to 2.3 ng ml-1 h-1, but at no time during treatment did this decrease correlate with that of blood pressure. 5. Guanfacine treatment was accompanied by relatively few and mild side-effects.
摘要
- 对24例高血压患者（WHO I - III级）研究了胍法辛治疗12周对血压和血浆肾素活性的影响。2. 每日服用3毫克胍法辛固定剂量1周后，收缩压、舒张压和平均血压值显著降低：治疗前为197/115/149（收缩压/舒张压/平均）毫米汞柱，降至166/97/126毫米汞柱。在不同剂量治疗4周后，血压降至157/91/118毫米汞柱，治疗12周后稳定在147/83/109毫米汞柱。在整个观察期内心率基本保持不变。3. 在运动期间，治疗期间血压和心率升高的程度与治疗前相同。所有患者均未出现直立性低血压。4. 治疗期间肾素值从3.3降至2.3纳克/毫升·小时，但在治疗期间的任何时候，这种降低与血压的降低均无相关性。5. 胍法辛治疗伴随的副作用相对较少且轻微。
相似文献
1
Effect of guanfacine on blood pressure and renin activity in hypertensive patients.
Br J Clin Pharmacol. 1980;10 Suppl 1(Suppl 1):91S-96S. doi: 10.1111/j.1365-2125.1980.tb04913.x.
2
[Blood pressure and renin under treatment of hypertension with guanfacine (author's transl)].
MMW Munch Med Wochenschr. 1980 Jan 25;122(4):137-40.
3
Blood pressure, heart rate, catecholamines and plasma renin activity following institution and withdrawal of guanfacine treatment in moderate hypertension.
Br J Clin Pharmacol. 1980;10 Suppl 1(Suppl 1):109S-114S. doi: 10.1111/j.1365-2125.1980.tb04916.x.
4
Guanfacine in essential hypertension: effect on blood pressure, plasma noradrenaline concentration and plasma renin activity.
Br J Clin Pharmacol. 1980;10 Suppl 1(Suppl 1):97S-101S. doi: 10.1111/j.1365-2125.1980.tb04914.x.
5
Guanfacine: a new centrally-acting antihypertensive agent.
Pharmatherapeutica. 1981;2(8):513-6.
6
An ambulatory trial of guanfacine.
Br J Clin Pharmacol. 1980;10 Suppl 1(Suppl 1):103S-107S. doi: 10.1111/j.1365-2125.1980.tb04915.x.
7
Evaluation of long-term treatment of essential hypertension with guanfacine.
Br J Clin Pharmacol. 1980;10 Suppl 1(Suppl 1):61S-64S. doi: 10.1111/j.1365-2125.1980.tb04906.x.
8
Hemodynamic and endocrine responses to guanfacine in normotensive volunteers and hypertensive patients.
Am J Cardiol. 1986 Mar 28;57(9):22E-26E. doi: 10.1016/0002-9149(86)90719-8.
9
A new centrally action antihypertensive agent guanfacine (BS 100-141).
Arzneimittelforschung. 1977;27(3):674-6.
10
Comparison of once-daily guanfacine and twice-a-day methyldopa in the treatment of mild to moderate hypertension.
Clin Ther. 1985;7(2):199-204.
引用本文的文献
1
Guanfacine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of hypertension.
Drugs. 1986 Apr;31(4):301-36. doi: 10.2165/00003495-198631040-00003.
本文引用的文献
1
Differences in psychic performance with guanfacine and clonidine in normotensive subjects.
Br J Clin Pharmacol. 1980;10 Suppl 1(Suppl 1):71S-80S. doi: 10.1111/j.1365-2125.1980.tb04909.x.
2
Hemodynamic changes at rest and during exercise in long-term clonidine therapy of essential hypertension.
Acta Med Scand. 1974 Jan-Feb;195(1-2):111-5. doi: 10.1111/j.0954-6820.1974.tb08106.x.
3
Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects.
J Clin Endocrinol Metab. 1969 Oct;29(10):1349-55. doi: 10.1210/jcem-29-10-1349.
4
Pharmacological actions of the antihypertensive agent N-amidino-2-(2,6-dichlorophenyl)acetamide hydrochloride (BS 100-141).
Arzneimittelforschung. 1975 Oct;25(10):1483-91.
5
Plasma renin activity, blood pressure and sodium excretion during treatment with clonidine.
Acta Med Scand. 1975 Jun;197(6):457-61. doi: 10.1111/j.0954-6820.1975.tb04951.x.
6
Renin and aldosterone suppression in the antihypertensive action of clonidine.
Am J Cardiol. 1976 Nov 23;38(6):825-30. doi: 10.1016/0002-9149(76)90361-1.
7
[Standardization of orthostatic stress. Comparison of orthostatic stress under laboratory and routine conditions].
Med Welt. 1976 Sep 17;27(38):1789-93.
8
Central and reflex control of renin release.
Prog Brain Res. 1977;47:397-407. doi: 10.1016/S0079-6123(08)62743-0.
9
Role of renin and aldosterone suppression in the antihypertensive mechanism of clonidine.
Am J Med. 1978 Oct;65(4):614-8. doi: 10.1016/0002-9343(78)90849-5.
10
Clonidine in primary hypertension: effects on blood pressure, plasma renin activity, plasma and urinary aldosterone.
Curr Ther Res Clin Exp. 1977 Jan;21(1):10-20.
Zotero 插件